Adeno-associated virus (AAV) products are commonly used in gene therapy as a means of delivering therapeutic genes to target cells. AAVnerGene Inc is a company dedicated to providing innovative AAV-related products and technologies to researchers and clinicians working in the field of gene therapy. By offering a range of AAV plasmids, premade AAV vectors, empty AAV particles, AAV serotype testing kits, and AAV capsid libraries, AAVnerGene is able to support a broad range of gene therapy research and development projects.
AAV Plasmids
AAV plasmids are used to produce AAV vectors. The traditional AAV production system involves three plasmids: pGOI plasmid contains the AAV inverted terminal repeats (ITRs) that flank the gene of interest (transgene). pRep-Cap plasmid encodes the AAV replication and capsid proteins. pHelper plasmid provides the necessary Ad functions for AAV production, including E2A, E4orf6 and VA RNA.
AAVnerGene has developed innovative technologies for AAV vector production, including the AAVone System and AAVdual System. These systems are designed to reduce plasmid numbers, improve AAV vector packaging efficiency, reduce production costs, and offer customers the flexibility to choose the systems that best fits their specific needs, ultimately contributing to the goal of increasing the accessibility and affordability of AAV gene therapy. pAAVone and pAAVdual plasmids are designed to produce AAV vectors with AAVone System and AAVdual System, respectively.
Premade AAVs
Premade AAV vectors can be used directly for gene delivery or modified to suit specific research or therapeutic needs. The premade AAV vectors are available in various serotypes, promoters, and reporters, allowing researchers to choose the most suitable vector for their specific research application.
AAVnerGene offers over a thousand of known serotypes of AAV vectors to customer for quickly determination of the AAV vector specificity for different types of cells, while multiple promoters with reporter genes make it easy to determine and tracking the level and timing of a specific gene expression.
AAV Serotype Testing Kits
AAV serotype testing kits are allow researchers to test the efficiency of different AAV serotypes and variants in delivering genes to target cells. 16 most common serotypes of AAV vectors (AAV1, AAV2, AAV3B, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVDJ, AAVrh.10, AAVrh.74, AAV2-retro) are included in each kit. Customers can choose different promoters and reporters used in the kits.
AAV Capsid Libraries
AAVnerGene Offers two different types of AAV capsid libraries:
AAV capsid libraries(I) are known capsid library build on our ATHENA I platform. They are used to systematically evaluate different known AAV serotypes or variants. In the ATHENA I library, each capsid variant was assigned to three different DNA barcodes. All the tissue-specific AAV capsid libraries(I) include 9 reported tissue-targeting AAV variants and 16 common used AAV serotypes.
AAV Capsid Libraries(II) are random peptide insert library build on our ATHENA II platform. In those libraries, Cap gene with random peptide are driven by a CAG/P40 hybrid promoter. AAVnerGene offers high complexity (>1e9) AAV Capsid Libraries(II) with different AAV templates, different insert regions and different insert lengths. They are used to evolute novel AAV capsids with tissue-specific tropism.
Empty AAV particles
Empty AAV particles are indeed versatile tools with various applications in AAV-based gene therapy development, quality control, and basic research. There is two different types of empty particles:
- Truly-Empty AAV Particles: Truly-empty AAV particles are intentionally created through a specialized production process where only the necessary components for AAV replication (e.g., ad helper and AAV helper) are provided. Truly-empty AAV particles do not contain any genetic material, making them entirely empty capsids. They lack the therapeutic transgene that is typically present in AAV vectors.
- Byproduct-Empty AAV Particles: Byproduct-empty AAV particles are unintentional outcomes that can arise during the production of regular AAV vectors. They are not deliberately generated but are a result of the production process. Byproduct-empty AAV particles may contain partial or incomplete genomes.